Royalty Pharma Plc (RPRX)

Currency in USD
59.11
+1.32(+2.28%)
Real-time Data·
RPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
57.6559.16
52 wk Range
34.0860.44
Key Statistics
Prev. Close
57.79
Open
57.75
Day's Range
57.65-59.16
52 wk Range
34.08-60.44
Volume
1.5M
Average Volume (3m)
3.57M
1-Year Change
64.8355%
Book Value / Share
15.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RPRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
64.75
Upside
+9.54%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Royalty Pharma Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 64.75
(+9.54% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy62.00+5.00%58.00MaintainAug 07, 2026
Morgan Stanley
Buy65.00+10.08%64.00MaintainAug 06, 2026
BofA Securities
Buy63.00+6.69%62.00MaintainAug 05, 2026
JPMorgan
Buy58.00-1.78%50.00MaintainMay 07, 2026
Morgan Stanley
Buy64.00+8.38%63.00MaintainMay 07, 2026

Royalty Pharma Plc Earnings Call Summary for Q2/2026

  • Royalty Pharma posted Q2 portfolio receipts of $773M, up 6% YoY, with total receipts rising 14%, marking 25th consecutive quarter of growth.
  • Company raised FY2026 guidance for second straight quarter: portfolio receipts now $3.4B-$3.5B, royalty receipt growth lifted to 7%-10% from 4%-8%.
  • Firm maintains $4B+ financial flexibility with BBB ratings across all three major credit agencies; leverage stands at 2.8x debt-to-EBITDA.
  • Management reaffirmed 2030 target of $4.7B in portfolio receipts, highlighting expansion in development-stage assets and China opportunities.
  • Stock rose 0.63% to $57.84 in premarket trading, near 52-week high of $60.44, reflecting solid but largely anticipated results.
Last Updated: 2026/08/05, 15:10
Read Full Transcript

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
1,32 / 1,29
Revenue / Forecast
773M / 800,05M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.86%
Dividend Yield
1.63%
Industry Median 2.25%
Annualised payout
0.94
Paid quarterly
5-Years Growth
+7.29%
Growth Streak

RPRX Income Statement

Compare RPRX to Peers and Sector

Metrics to compare
RPRX
Peers
Sector
Relationship
P/E Ratio
32.3x12.7x−0.4x
PEG Ratio
−1.59−0.520.00
Price/Book
5.0x3.6x2.6x
Price / LTM Sales
13.3x2.4x3.1x
Upside (Analyst Target)
12.5%22.4%47.5%
Fair Value Upside
Unlock−3.0%5.9%Unlock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Employees
100

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
185,25M41,60%10,74B
Other Institutional Investors
186,20M41,82%10,79B
Public Companies & Retail Investors
73,83M16,58%4,28B
Total
445,28M100,00%25,81B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Capital Research and Management Company10,29%45 809 1332 655 555
Morgan Stanley Investment Management Inc.8,29%36 931 1082 140 896

FAQ

What Is the Royalty Pharma (RPRX) Stock Price Today?

The Royalty Pharma stock price today is 59,11 USD.

What Stock Exchange Does Royalty Pharma Trade On?

Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Royalty Pharma?

The stock symbol for Royalty Pharma is "RPRX."

Does Royalty Pharma Pay Dividends? What’s The Current Dividend Yield?

The Royalty Pharma dividend yield is 1.63%.

What Is the Royalty Pharma Market Cap?

As of today, Royalty Pharma market cap is 33,94B USD.

What Is Royalty Pharma's Earnings Per Share (TTM)?

The Royalty Pharma EPS (TTM) is 1,86.

When Is the Next Royalty Pharma Earnings Date?

Royalty Pharma will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is RPRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Royalty Pharma Stock Split?

Royalty Pharma has split 0 times.

How Many Employees Does Royalty Pharma Have?

Royalty Pharma has 100 employees.

What is the current trading status of Royalty Pharma (RPRX)?

As of Aug 12, 2026, Royalty Pharma (RPRX) is trading at a price of 59,11 USD, with a previous close of 57,79 USD. The stock has fluctuated within a day range of 57,65 USD to 59,16 USD, while its 52-week range spans from 34,08 USD to 60,44 USD.

What Is Royalty Pharma (RPRX) Price Target According to Analysts?

The average 12-month price target for Royalty Pharma is 64,75 USD, with a high estimate of 70 USD and a low estimate of 61 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9,54% Upside potential.

What Is the RPRX Premarket Price?

RPRX's last pre-market stock price is 57,90 USD. The pre-market share volume is 13 400,00, and the stock has decreased by 0,11, or 0,19%.

What Is the RPRX After Hours Price?

RPRX's last after hours stock price is 58,02 USD, the stock has decreased by 0,23, or 0,40%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.